John Mackay - Sartorius Stedim Sales Marketing

All Insiders . France . 
Stock . Sartorius Stedim Biotech . Stakeholders . Insider . John Mackay
DIM Stock  EUR 168.60  0.55  0.33%   

Insider

John Mackay is Sales Marketing of Sartorius Stedim Biotech
Age 61
Phone33 4 42 84 56 00
Webhttps://www.sartorius.com

Sartorius Stedim Management Efficiency

The company has return on total asset (ROA) of 0.1548 % which means that it generated a profit of $0.1548 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.4143 %, meaning that it generated $0.4143 on every $100 dollars invested by stockholders. Sartorius Stedim's management efficiency ratios could be used to measure how well Sartorius Stedim manages its routine affairs as well as how well it operates its assets and liabilities.
Sartorius Stedim Biotech has accumulated 1.02 B in total debt with debt to equity ratio (D/E) of 0.5, which is about average as compared to similar companies. Sartorius Stedim Biotech has a current ratio of 1.46, which is within standard range for the sector. Debt can assist Sartorius Stedim until it has trouble settling it off, either with new capital or with free cash flow. So, Sartorius Stedim's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Sartorius Stedim Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Sartorius to invest in growth at high rates of return. When we think about Sartorius Stedim's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Gabriel JuliaEurofins Scientific SE
N/A
Tanneguy BouailleDassault Systemes SE
68
Bernard CharlesDassault Systemes SE
66
Rouven BergmannDassault Systemes SE
50
Gilles MartinEurofins Scientific SE
60
Victoire MargerieDassault Systemes SE
N/A
Laurence BaucherBarthsDassault Systemes SE
N/A
Timothy OostdykEurofins Scientific SE
N/A
Laurent LebrasEurofins Scientific SE
N/A
Daniel JulienTeleperformance SE
71
Pierre CharbonnierBiomerieux SA
N/A
Valerie HanoteEurofins Scientific SE
57
Sylvain MorgeauBiomerieux SA
N/A
Agustin GrisantiTeleperformance SE
50
Yannis TourcomanisTeleperformance SE
N/A
Valerie LeyldeBiomerieux SA
N/A
Philippe MareineWorldline SA
52
Mark MillerBiomerieux SA
N/A
Quy NguyenNgocTeleperformance SE
54
Joachim ReicheltEurofins Scientific SE
N/A
Florence VerzelenDassault Systemes SE
45
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG. SARTORIUS STED operates under Medical Instruments Supplies classification in France and is traded on Paris Stock Exchange. It employs 10409 people. Sartorius Stedim Biotech (DIM) is traded on Euronext Paris in France and employs 11,934 people.

Management Performance

Return On Equity0.41
Return On Asset0.15

Sartorius Stedim Biotech Leadership Team

Elected by the shareholders, the Sartorius Stedim's board of directors comprises two types of representatives: Sartorius Stedim inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Sartorius. The board's role is to monitor Sartorius Stedim's management team and ensure that shareholders' interests are well served. Sartorius Stedim's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Sartorius Stedim's outside directors are responsible for providing unbiased perspectives on the board's policies.
Petra Kirchhoff, Head IR
Heiko Imhl, VP Relations
Olivier Guitard, Head BPS
Joachim Kreuzburg, Chairman CEO
John Mackay, Sales Marketing
Benedikt Orzelek, Head Relations

Sartorius Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Sartorius Stedim a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity0.41
Return On Asset0.15
Profit Margin0.25 %
Operating Margin0.32 %
Current Valuation31.28 B
Shares Outstanding92.17 M
Shares Owned By Insiders73.81 %
Shares Owned By Institutions13.83 %
Price To Earning80.53 X
Price To Book13.32 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Other Information on Investing in Sartorius Stock

Sartorius Stedim financial ratios help investors to determine whether Sartorius Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sartorius with respect to the benefits of owning Sartorius Stedim security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY